United Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of United Therapeutics generated cash of $978,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$11,900,000 last year. Net change in cash is therefore $246,500,000.
Cash Flow
| 2014 | 355.3M | 338.5M | -576.6M |
|---|---|---|---|
| 2015 | 382.8M | 503.6M | -447M |
| 2016 | 643.6M | 48.3M | -497.7M |
| 2017 | 474.2M | -835.6M | 43.3M |
| 2018 | 778.4M | -820.6M | 6.3M |
| 2019 | -206.6M | -335.4M | 611.2M |
| 2020 | 755.7M | -738.5M | -16.9M |
| 2021 | 598.2M | -486.9M | 44.8M |
| 2022 | 802.5M | -811.5M | 75.4M |
| 2023 | 978M | -719.6M | -11.9M |
UTHR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 961.2M | 894.8M | 738.7M | 738.4M | 669.2M | 705.1M | 1.02B | 831.8M | 397.69M | 284.25M |
Operating activities | ||||||||||
Net income | 984.8M | 727.3M | 475.8M | 514.79M | -104.5M | 589.2M | 417.9M | 713.7M | 651.6M | 340.1M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 53.2M | 51.3M | 49.9M | 49.9M | 45.9M | 35.9M | 31M | 31.6M | 32.9M | 32.2M |
Stock-based compensation expense | 39.1M | 106.8M | 138.5M | 163.8M | 45.4M | 0 | 73.5M | 12.1M | 280.25M | 190.05M |
| Deferred income tax benefit | 39.1M | 106.8M | 138.5M | 163.8M | 45.4M | 0 | 73.5M | 12.1M | 280.25M | 190.05M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -58.5M | -21.7M | -41.3M | -6M | 24.4M | 121.4M | -82.7M | -21.7M | -30.5M | -35.7M |
Inventories | -13.6M | -13.4M | -7.5M | 10.3M | 12.9M | 9.3M | -500K | -24.5M | -6.8M | -21M |
Accounts payable | 57.1M | 150.6M | 112.9M | -16.8M | -16.3M | -11M | 66.2M | 600K | 16.97M | -6.75M |
Cash generated by operating activities | 978M | 802.5M | 598.2M | 755.7M | -206.6M | 778.4M | 474.2M | 643.6M | 382.8M | 355.3M |
Investing activities | ||||||||||
Purchases Of Investments | -2.51B | -1.70B | -1.89B | -2.30B | -1.27B | -867M | -830.6M | -38.9M | -116.99M | -163.67M |
Investments In Property Plant And Equipment | -230.4M | -138.8M | -120.8M | -59.3M | -83.7M | -184.4M | -86.3M | -43.2M | -49.79M | -47.43M |
Acquisitions Net | -89.2M | 7.1M | 366.1M | 681.6M | -20.5M | -124.1M | 8.3M | -2.1M | 0 | 0 |
Cash generated by investing activities | -719.6M | -811.5M | -486.9M | -738.5M | -335.4M | -820.6M | -835.6M | 48.3M | 503.6M | 338.5M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 55.6M | 38.5M | 0 | 19.5M | 0 | 12M | 0 | 3.32M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -13.8M | -11.4M | -10.8M | -3.7M | -2.1M | 0 | -250M | -500M | -394.5M | -483.1M |
Repayments of term debt | -100M | 0 | 0 | -50M | 600M | -250M | 250M | -8.8M | -133.2M | -177.8M |
Cash used in financing activities | -11.9M | 75.4M | 44.8M | -16.9M | 611.2M | 6.3M | 43.3M | -497.7M | -447M | -576.6M |
Net Change In Cash | 246.5M | 66.4M | 156.1M | 300K | 69.2M | -35.9M | -317.9M | 191.2M | 434.10M | 113.43M |
Cash at end of period | 1.20B | 961.2M | 894.8M | 738.7M | 738.4M | 669.2M | 705.1M | 1.02B | 831.79M | 397.69M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |